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Abstract 
Background: Hemophilia B is a rare congenital bleeding disorder that has a significant negative impact on patients’ 
functionality and health-related quality of life. The standard of care for severe hemophilia B in the United States is pro-
phylactic factor IX replacement therapy, which incurs substantial costs for this lifelong condition. Accurate estimates 
of the burden of hemophilia B are important for population health management and policy decisions, but have 
only recently accounted for current management strategies. The ‘Cost of Severe Hemophilia across the US: a Socio-
economic Survey’ (CHESS US) is a cross-sectional database of medical record abstractions and physician-reported 
information, completed by hematologists and care providers. CHESS US+ is a complementary database of completed 
questionnaires from patients with hemophilia. Together, CHESS US and CHESS US+ provide contemporary, compre-
hensive information on the burden of severe hemophilia from the provider and patient perspectives. We used the 
CHESS US and CHESS US+ data to analyze the clinical, humanistic, and economic burden of hemophilia B for patients 
treated with factor IX prophylaxis between 2017 and 2019 in the US.
Results: We conducted analysis to assess clinical burden and direct medical costs from 44 patient records in CHESS 
US, and of direct non-medical costs, indirect costs, and humanistic burden (using the EQ-5D-5L) from 57 patients in 
CHESS US+. The mean annual bleed rate was 1.73 (standard deviation, 1.39); approximately 9% of patients experi-
enced a bleed-related hospitalization during the 12-month study period. Nearly all patients (85%) reported chronic 
pain, and the mean EQ-5D-5L utility value was 0.76 (0.24). The mean annual direct medical cost was $614,886, driven 
by factor IX treatment (mean annual cost, $611,971). Subgroup analyses showed mean annual costs of $397,491 and 
$788,491 for standard and extended half-life factor IX treatment, respectively. The mean annual non-medical direct 
costs and indirect costs of hemophilia B were $2371 and $6931.
Conclusions: This analysis of patient records and patient-reported outcomes from CHESS US and CHESS US+ pro-
vides updated information on the considerable clinical, humanistic, and economic burden of hemophilia B in the US. 
Substantial unmet needs remain to improve patient care with sustainable population health strategies.
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Background
Hemophilia B is a rare X-linked recessive genetic 
disorder characterized by abnormal bleeding due 
to defective or missing clotting factor IX (FIX) [1]. 
Open Access
*Correspondence:  n.li@uniqure.com
3 uniQure Inc, 113 Hartwell Avenue, Lexington, MA 02421, USA
Full list of author information is available at the end of the article
Page 2 of 8Burke et al. Orphanet J Rare Dis          (2021) 16:143 
Approximately 6000 people in the US have hemo-
philia B [2], which occurs predominantly in males [3]. 
The severity of hemophilia B is based on the endoge-
nous FIX level. Mild (FIX activity 5 to 40% IU/dL) and 
moderate (1 to < 5% IU/dL) hemophilia B are generally 
associated with excessive bleeding with trauma, and 
sometimes, spontaneous bleeding [4–7]. In severe dis-
ease (FIX level < 1  IU/dL), spontaneous and recurrent 
bleeding into joints is frequent, leading to deformity, 
arthritis at an early age, and long-term sequelae [8–11].
Hemophilia B is known to cause substantial func-
tional limitations and reduced health-related quality 
of life (HRQoL) [12–14] related to bleeding and joint 
damage, and other disease-related complications [15, 
16]. Prophylactic administration of FIX replacement 
therapy is the standard of care for severe hemophilia B 
in the US [17–20], and has helped improve life expec-
tancy to approach that of the general population [21]. 
Extended half-life (EHL) and standard half-life (SHL) 
formulations are administered often, every 1–2  weeks 
and 2–3 times per week, respectively, which incurs 
a treatment burden on patients [22, 23] and a notable 
economic burden to healthcare systems and society 
[24–27].
Studies of the nonclinical burden of hemophilia B often 
focus on the cost of FIX prophylaxis, which accounts for 
the majority of direct costs, as analyzed in a recent analy-
sis of administrative claims and a systematic literature 
review [26, 28]. Few recent studies have examined indi-
rect costs and non-medical direct costs, which comprise 
a smaller proportion of total costs but impose a consid-
erable burden on patients, their caregivers, and society 
[27, 29]. The European CHESS study reported lost wages 
for both patients and caregivers, and substantial costs to 
patients related to the demands of managing both the 
disease and lifelong treatment [30]. Such estimates of 
patient-centered burden have been less well character-
ized in the United States since the advent of newer treat-
ment options, such as EHL prophylaxis. The hemophilia 
treatment advances that have prolonged life expectancy 
have also brought attention to examining the quality of 
those additional life-years, requiring deeper understand-
ing of the impact of disease and treatment on all aspects 
of patients’ lives. As such, accounting for both direct and 
indirect costs is important for evidence-based policy and 
population health management decisions.
The ‘Cost of Severe Hemophilia across the US: a Socio-
economic Survey’ (CHESS US) study was designed to 
provide population-based insights on the real-world bur-
den of severe hemophilia in the US. We used the CHESS 
US datasets to further characterize the clinical, human-
istic, and economic burden of severe hemophilia B for 
patients treated with FIX prophylaxis in the US.
Results
Patients
Of 576 patients in CHESS US, 132 (23%) had severe 
hemophilia B of whom 33% (44/132) had an evaluable 
record of continuous FIX prophylaxis and were included 
in the analysis (20 received SHL, 24 received EHL). Of 
the 88 patients with severe haemophilia B who were 
excluded, 54 had on-demand treatment, 18 had inter-
mittent prophylaxis, 1 had no record of treatment, and 
15 with continuous prophylaxis had inadequate treat-
ment information (n = 2) or < 15 IU/kg dose per infusion 
(n = 13). Of 356 patients in CHESS US+, 97 (27%) had 
severe hemophilia B of whom 59% (57/97) had a record 
of FIX prophylaxis and were included in the analysis (22 
received SHL, 35 received EHL).
Baseline demographic and clinical characteristics 
for both analysis cohorts are summarized in Table 1. In 
CHESS US, patients were on average 28  years old and 
had a mean weight of 75.7  kg. Patients in CHESS US+ 
appeared to be slightly older (mean age, 35.6 years) and 
slightly heavier (mean weight, 85.6  kg). Across cohorts, 
half of patients reported full-time employment (52% and 
49%, respectively), and nearly all patients reported insur-
ance coverage (82% and 100%). The most common medi-
cal comorbidities were anxiety, depression, osteoarthritis, 
and type 2 diabetes. We observed a low prevalence of 
hepatitis B, hepatitis C, and human immunodeficiency 
virus (HIV) in both cohorts, consistent with the average 
age in each cohort.
Table 1 Baseline demographics and clinical characteristics
HIV human immunodeficiency virus
CHESS US
 n = 44
CHESS US+
n = 57
Age, mean (SD) (years) 27.64 (11.05) 35.84 (12.69)
Weight, mean (SD) (kg) 75.71 (13.42) 85.57 (21.15)
Comorbidities, n (%)
 Anxiety 1 (2.3%) 16 (28.1%)
 Depression 3 (6.8%) 13 (22.8%)
 Type 2 diabetes mellitus 3 (6.8%) 1 (1.8%)
 Hepatitis B 0 8 (14.0%)
 Hepatitis C 2 (5%) 0
 HIV 0 5 (8.8%)
 Osteoarthritis 0 12 (21.1%)
 Osteoporosis 0 1 (1.8%)
Employment status, n (%)
 Full-time employed 20 (52.3%) 28 (49.1%)
 Part-time employed 4 (9.1%) 14 (24.6%)
 Unemployed/Student/Retired 17 (38.6%) 15 (26.3%)
Insurance coverage, n (%)
 Yes 36 (81.8%) 57 (100%)
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Clinical outcomes
The mean annual bleed rate (ABR) from CHESS US was 
1.73 (SD 1.39; median 2.0; Table 2). At least one bleed-
related hospitalization was reported by 9.1% of CHESS 
US patients in the previous year, with a mean length of 
stay of 0.3 days. One-fifth (18%) of patients reported at 
least one target joint, and 11% of patients reported at 
least one problem joint.
Humanistic outcomes
The mean reported EQ-5D-5L score was 0.74 (SD 
0.26). More than one-quarter (28%) of patients from 
CHESS US+ reported chronic pain ratings ≥ 6/10, 
and half (56%) reported pain 1–5/10 on average over 
the past year. Slightly more than half of patients (56%) 
from CHESS US+ reported that their daily lives were 
compromised by hemophilia B, and nearly all (91%) 
reported adapting their FIX treatment schedule to 
account for anticipated physical activity demands 
(Table 3).
Economic outcomes
The annual FIX usage per patient from CHESS US was 
257,216  IU (Fig.  1), with an annual cost of $611,971. 
Usage of FIX among those who received SHL was 
287,141  IU, with a corresponding annual cost of 
$397,491. For patients who received EHL, annual FIX 
usage was 232,278  IU with a corresponding annual 
cost of $788,861. Total annual direct medical costs of 
hemophilia B from CHESS US were $614,886, driven 
almost entirely by the cost of FIX treatment ($611,971; 
Table 4). The annual direct medical cost of hemophilia 
B excluding FIX treatment was $2885.
Annual non-medical direct costs from CHESS US+ 
were $2371, driven primarily by caregiver expenses 
($1566 for professional and informal caregiving; Table 5). 
Annual indirect costs of $6931 were driven by hemo-
philia-related unemployment and early retirement.
Discussion
Despite recent improvements in treatment options, our 
analysis of the CHESS US and CHESS US+ datasets have 
shown a persistent and comprehensive clinical, human-
istic, and economic burden of hemophilia B on patients 
receiving FIX prophylaxis, with substantial FIX treat-
ment-driven costs to payers and society. Bleeding-related 
health resource use was accompanied by chronic pain 
and compromised employment due to hemophilia, along 
with non-medical and indirect costs related to self-man-
agement and use of professional or informal caregivers. 
These personal and societal costs were observed in addi-
tion to high treatment costs, emphasizing the remaining 
unmet needs for reducing the burden of hemophilia B 
with sustainable population health strategies and treat-
ment options.
Despite receiving FIX prophylaxis, patients with 
severe hemophilia B continue to experience break-
through bleeding and may eventually develop hemophilic 
arthropathy [31]. We observed target joints in approxi-
mately 20% of patients, and a mean ABR of 1.73 that was 
consistent with other recent real-world studies [27, 32]. 
These breakthrough bleeds could be related to repeated 
FIX trough periods, during which patients are exposed 
to higher risk of bleeding [33, 34], and the frequent infu-
sions that may compromise treatment adherence and 
limit the real-world effectiveness of FIX prophylaxis [33, 




 Mean (SD) 1.73 (1.39)
 Median (range) 2.00 (0–5)
Bleed-related hospitalizations
 One or more admissions 4 (9.1%)
 Inpatient stay, mean (SD) 0.34 (1.22)
 ICU stay, mean (SD) 0.23 (0.86)
Target joints
 0 TJ 36 (81.8%)
 1 TJ 4 (9.1%)
 2+ TJ 4 (9.1%)
Problem joints
 0 PJ 39 (88.6%)
 1 PJ 2 (4.5%)
 2+ PJ 3 (6.8%)




 Mean (SD) 0.74 (0.26)
Chronic pain
 No pain 9 (15.8%)
 Pain level 1–5 32 (56.1%)
 Pain level 6–10 16 (28.1%)
Daily life compromised by hemophilia
 Yes 32 (56.1%)
 No 25 (43.9%)
Adapt treatment regimen (physical activity)
 Yes 52 (91.2%)
 No 5 (8.8%)
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34]. Taken together, our findings suggest that even with 
access to prophylaxis, patients with severe hemophilia 
B remain at considerable risk for arthropathy and long-
term damage.
Our findings are consistent with previous reports of 
the burden hemophilia B and continuous FIX treatment 
impose on patients and their families [12–14]. Nearly 
all (85%) patients in CHESS US+ reported some level 
of chronic pain, which is a patient-important outcome 
highlighted in the US Food and Drug Administration 
(FDA) Patient-Focused Drug Development (PFDD) 
initiative for hemophilia [35]. We observed a corre-
sponding level of humanistic burden, with an average 
EQ-5D-5L utility value of 0.74 which is consistent with 
the range of values reported in a recent systematic lit-
erature review [36]. More than half of patients reported 
that hemophilia had compromised their daily lives, and 
nearly all reported an influence of FIX treatment sched-
uling on their physical activity.
b
a
Fig. 1 Annual FIX usage (a) and costs (b). EHL extended half-life, SHL standard half-life
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We also observed a substantial economic burden of 
hemophilia B and its treatment to US payers, with an 
annual direct medical cost for severe hemophilia B of 
$614,886, driven by the cost of FIX replacement ther-
apy ($611,971, or 99% of total direct medical costs). The 
annual cost of EHL FIX prophylaxis was nearly double 
that for SHL FIX ($788,861 and $397,491, respectively). 
Our findings from medical record abstractions (CHESS 
data analyses) are consistent with recent analyses of 
administrative claims from large commercial payer data-
bases [26], but provide additional context from phy-
sician- and patient-reported clinical and humanistic 
burden. Similar to our findings, Tortella and colleagues 
reported 30% lower mean monthly dispensed IUs and 
54% higher mean monthly costs for EHL versus SHL reg-
imens among 296 commercially insured US patients with 
moderate or severe hemophilia B [26]. While this study 
was not meant to compare EHL versus SHL regimens, 
it is important to note that assessment of direct costs 
only did not capture the potential clinical benefits and 
reduced treatment burden associated with an EHL regi-
men [37, 38]. In addition to FIX replacement therapy, the 
costs of medical encounters such as hospitalizations (and 
intensive care unit admissions) and physician office vis-
its represent additional financial burden to the healthcare 
system.
Our study also quantified the direct non-medical and 
indirect costs associated with hemophilia B and FIX 
replacement therapy. Direct non-medical costs were 
mainly driven by caregiver expenses, both professional 
and informal, and indirect costs were comprised largely 
of hemophilia-related unemployment and early retire-
ment. Findings were consistent with those of the pro-
spective, longitudinal Hemophilia Utilization Group 
Studies Part Vb (HUGS Vb) study of patients with hemo-
philia B from 10 HTCs in the US [27]. The direct non-
medical and indirect costs associated with hemophilia B 
may comprise a relatively small proportion of the total 
cost, but nonetheless represent a significant burden 
to patients, employers, and society in the form of lost 
income and productivity for both patients and caregivers 
[27, 39].
These findings should be interpreted in the context of 
certain strengths and limitations. While we were able to 
include patient-reported outcomes, any retrospective, 
cross-sectional study is subject to certain limitations. 
Both the chart review and patient survey could be prone 
to selection bias, recall bias, and/or potential errors in 
data abstraction. We used data from two distinct cohorts 
for clinical and economic burden vs humanistic, and 
reported the results separately. Clinical burden and direct 
medical costs were based on physician-reported data 
in the CHESS US cohort, which may not have reflected 
the exact costs incurred by the ultimate payer. Since this 
analysis focused on patients without inhibitors receiving 
consistent prophylaxis treatment, our findings are not 
generalizable to populations with inhibitors and those 
receiving on-demand treatment or periodic prophylaxis. 
Other unmeasured variables may also limit generaliz-
ability of these findings to specific types of patients with 
hemophilia B in the US. Nonetheless, our findings were 
consistent with reports from other data sources, and sug-
gest that the CHESS US and CHESS US+ datasets are 
well suited to provide insights into the burden of hemo-
philia to patients and society in the US.
Conclusions
We observed a substantial clinical and humanistic burden 
of hemophilia B on patients receiving FIX prophylaxis 
in the US, and substantial FIX treatment-driven costs 
to the society. The CHESS US and CHESS US+ cohorts 
Table 4 Economic outcomes: direct medical costs
Costs were calculated in 2019 USD based on Factor IX consumption reported by 
the physicians, using Factor IX unit costs from IBM® Micromedex® RED BOOK®
Mean (SD), unless noted CHESS US
n = 44
Hemophilia consultation $271 ($113)
Other consultation $73 ($66)
Blood tests $191 ($116)
Other tests $87 ($268)
Ward inpatient $2194 ($7845)
ICU $4123 ($14,284)
Factor IX $611,971 ($497,281)
Total direct medical cost (N = 44)—excluding FIX $2885 ($7857)
Total direct medical cost (N = 44)—including FIX $614,886 ($498,839)
Table 5 Economic outcomes: non-medical and indirect costs
Mean (SD), unless noted CHESS US+
n = 57
Non-medical cost
 Alternative and complimentary therapies $150 (452)
 Devices and home alterations $28 (75)
 Over the counter medications $178 (323)
 Disability entitlement $116 (343)
 Transit $333 (351)
 Professional caregiver $947 (5081)
 Informal caregiver $619 (3179)
Indirect cost
 Absenteeism $760 (2286)
 Early retirement/unemployed due to hemophilia $6171 (16,640)
 Total non-medical cost $2371 (6184)
 Total indirect cost $6.931 (16,510)
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provided important insights for personalized patient care 
and population health management. Despite recent ther-
apeutic advances in the treatment of severe hemophilia 
B, tangible unmet needs remain to better serve patients 
with this lifelong condition in a sustainable manner.
Methods
Study design
Following a similar design and methodology as the 
original CHESS study in Europe [30], CHESS US is a 
cross-sectional database of information extracted from 
medical record notes and physician-reported informa-
tion, by hematologists and hemophilia care providers for 
adults with severe hemophilia A or B in the US. Patient 
demographics, symptoms, treatment information and 
healthcare resource use for 576 patients was abstracted 
by 100 hemophilia care providers into a patient record 
form (PRF). Providers were recruited between 2017 and 
2018. Each provider completed a PRF form with at least 
12 months of retrospective data from each patient [30].
To supplement the CHESS US database, CHESS US+ 
is a separate, cross-sectional database of patient-reported 
information and outcomes provided by adult patients 
with hemophilia A or B using a patient panel approach. 
Participants used a secure web-based platform to com-
plete a patient self-completion (PSC) form and respond 
to patient-reported outcome measures. The question-
naire collected information on out-of-pocket expendi-
tures for transportation, alternative and complimentary 
therapy (i.e., physical rehabilitation), and impact on pro-
ductivity and attendance at work. All forms were com-
pleted in 2019 and captured a retrospective period of 
12 months.
The CHESS US and CHESS US+ sample popula-
tions were drawn in approximate proportions to those 
with hemophilia A or B in the US population [40]. This 
study was governed and approved by the University 
of Chester Ethics Committee in partnership with the 
National Hemophilia Foundation (NHF). All data were 
pseudonymized.
Study population
The population for this analysis included patients from 
CHESS US and CHESS US+ with severe hemophilia 
B and no medical history of FIX inhibitors who were 
treated with continuous FIX prophylaxis. We excluded 
patients treated with on-demand therapy, patients with-
out information on type of FIX treatment (SHL or EHL), 
patients who received intermittent prophylaxis, and 
patients whose prophylactic dose was below 15  IU/kg 
(which was likely associated with data entry errors).
Study outcomes and analyses
Clinical outcomes included ABR, bleed-related hospitali-
zations, and joint health from CHESS US, and patient-
reported chronic pain from CHESS US+. Joint health 
was captured using both ‘target joints’ based on the Inter-
national Society on Thrombosis and Haemostasis (ISTH) 
definition [41] and ‘problem joints’ based on a clinician 
and patient consensus definition on chronically damage 
joints [42]. In this case, a ‘problem joint’ was defined as 
any joint that has been permanently damaged as a result 
of a bleeding disorder, with or without persistent bleed-
ing, and may involve chronic pain and/or limited range 
of movement due to compromised joint integrity such 
as chronic synovitis and/or hemophilic arthropathy [42]. 
Patients reported chronic pain over the last 12  months 
on a scale of 0–10 where 0 indicated “no pain” and 10 
indicated “extreme pain.” Comorbidities were reported 
by physicians based on review of the medical chart for 
CHESS US, and by patient-reported responses regard-
ing current diagnoses in CHESS US+ (“Are you currently 
diagnosed with any of the following conditions? [Check 
all that apply]”).
Humanistic outcomes from CHESS US+ included 
HRQoL and the impact of hemophilia B on daily life and 
physical activity. HRQoL was measured using the Euro-
QoL 5-Dimension 5-Level (EQ-5D-5L) with utility values 
derived from the recently published US value set [43].
Economic outcomes included FIX usage and direct 
medical costs from CHESS US, and non-medical and 
indirect costs from CHESS US+. All costs were reported 
in 2019 USD ($). The annual cost of FIX treatment was 
calculated based on FIX usage from CHESS US and 
FIX unit costs from IBM® Micromedex® RED BOOK® 
[44]. Direct medical costs included FIX consumption, 
consultations with hemophilia specialists and the mul-
tidisciplinary team, testing, hospital stay and ICU use. 
Non-medical costs included expenses such as use of 
professional caregiving, travelling to the Hemophilia 
Treatment Center (HTC), alternative and complimen-
tary therapies, devices and home alterations, over the 
counter medications, transfer payments, professional 
and informal caregiving, and transit costs. Indirect costs 
comprised the cost associated with absenteeism, presen-
teeism, and early retirement/forced unemployment due 
to disease burden, and were valued using the human cap-
ital approach. Productivity costs (losses) estimated the 
value of lost time from work due to haemophilia-related 
absenteeism and long-term disability using patient-
reported work impairment and mean reported earnings 
at a national level.
All outcomes were summarized using descriptive sta-
tistics. Results are presented as means with standard 
deviations for continuous variables or as number and 
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proportion of patients for categorical variables. All analy-
ses were conducted using Stata 16.
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